SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
1-Year Return
71.55%
This Quarter Return
+1.96%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$479M
AUM Growth
+$31.4M
(+7%)
Cap. Flow
+$61M
Cap. Flow
% of AUM
12.75%
Top 10 Holdings %
Top 10 Hldgs %
50.4%
Holding
82
New
23
Increased
27
Reduced
15
Closed
14
Top Buys
| 1 |
KalVista Pharmaceuticals
KALV
|
$12.5M |
| 2 |
Soleno Therapeutics
SLNO
|
$11.9M |
| 3 |
89bio
ETNB
|
$10.3M |
| 4 |
Neurocrine Biosciences
NBIX
|
$8.03M |
| 5 |
Disc Medicine
IRON
|
$6.26M |
Top Sells
| 1 |
Pliant Therapeutics
PLRX
|
$17.3M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$15M |
| 3 |
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
|
$9.72M |
| 4 |
Scholar Rock
SRRK
|
$7.92M |
| 5 |
Cogent Biosciences
COGT
|
$7.18M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Mineralys Therapeutics
MLYS
$2.7B
| $5.37M | 1.1% |
+338,354
| New | +$5.37M |
|
27
Compugen
CGEN
$134M
| $4.23M | 0.86% |
2,895,430
+1,271,053
| +78% | +$1.86M |
|
28
Tarsus Pharmaceuticals
TARS
$2.43B
| $4.18M | 0.85% |
81,331
+15,376
| +23% | +$790K |
|
29
Alkermes
ALKS
$4.94B
| $4.12M | 0.84% |
+124,871
| New | +$4.12M |
|
30
Ocular Therapeutix
OCUL
$2.37B
| $4.04M | 0.83% |
+551,570
| New | +$4.04M |
|
31
BridgeBio Pharma
BBIO
$10.2B
| $3.84M | 0.78% |
+111,000
| New | +$3.84M |
|
32
Kura Oncology
KURA
$713M
| $3.84M | 0.78% |
+581,369
| New | +$3.84M |
|
33
Celldex Therapeutics
CLDX
$1.52B
| $3.74M | 0.76% |
205,962
-58,598
| -22% | -$1.06M |
|
34
Dianthus Therapeutics
DNTH
$853M
| $3.45M | 0.71% |
+190,334
| New | +$3.45M |
|
35
Madrigal Pharmaceuticals
MDGL
$9.65B
| $3.43M | 0.7% |
+10,344
| New | +$3.43M |
|
36
Cerus
CERS
$255M
| $3.41M | 0.7% |
2,456,537
+869,309
| +55% | +$1.21M |
|
37
TELA Bio
TELA
$63M
| $3.38M | 0.69% |
2,771,288
-294,361
| -10% | -$359K |
|
|
CNTA
38
Centessa Pharmaceuticals
CNTA
$2.11B
| $3.35M | 0.68% |
232,758
-366,194
| -61% | -$5.27M |
|
39
Trevi Therapeutics
TRVI
$854M
| $3.33M | 0.68% |
530,000
-204,234
| -28% | -$1.28M |
|
|
BPMC
40
DELISTED
Blueprint Medicines
BPMC
| $3.31M | 0.68% |
+37,345
| New | +$3.31M |
|
41
Structure Therapeutics
GPCR
$1.27B
| $3.26M | 0.67% |
188,069
+35,674
| +23% | +$618K |
|
42
Benitec Biopharma
BNTC
$365M
| $3.25M | 0.67% |
+250,000
| New | +$3.25M |
|
43
Liquidia Corp
LQDA
$2.48B
| $3.16M | 0.65% |
+214,057
| New | +$3.16M |
|
44
PTC Therapeutics
PTCT
$4.55B
| $3.08M | 0.63% |
+60,389
| New | +$3.08M |
|
|
MTSR
45
Metsera, Inc. Common Stock
MTSR
$3.77B
| $3.07M | 0.63% |
+112,759
| New | +$3.07M |
|
46
Biodesix
BDSX
$64.7M
| $2.56M | 0.52% |
4,098,406
-233,875
| -5% | -$146K |
|
47
Delcath Systems
DCTH
$408M
| $2.44M | 0.5% |
191,470
+36,145
| +23% | +$460K |
|
48
uniQure
QURE
$985M
| $2.16M | 0.44% |
203,400
+103,400
| +103% | +$1.1M |
|
49
Kiniksa Pharmaceuticals
KNSA
$2.65B
| $1.96M | 0.4% |
+88,215
| New | +$1.96M |
|
50
Solid Biosciences
SLDB
$428M
| $1.67M | 0.34% |
+452,239
| New | +$1.67M |
|